Evidence map›Paper›PMID 38712928›Full record

ArticleJournal of clinical microbiology2024

Comparison of BD Phoenix and disk diffusion to broth microdilution for determining cefepime susceptibility among carbapenem-resistant Enterobacterales.

Aliaa Fouad, Patricia J Simner, David P Nicolau, Tomefa E Asempa

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Cefepime susceptibility testing in AmpC-hyperproducing Enterobacter cloacae complex: limitations of routine methods and a pragmatic diagnostic approach.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  2. Article
  3. Genomic Analysis ofAntibiotics (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aliaa FouadCenter for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.ORCID 0009-0007-6467-1806
Patricia J SimnerDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-6134-151X
David P NicolauCenter for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.ORCID 0000-0002-4148-0165
Tomefa E AsempaCenter for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.ORCID 0000-0002-6268-0924

Funding

FDA HHS 75F40121C00148
6 · The paper itself

Abstract

There are increasing reports of carbapenem-resistant Enterobacterales (CRE) that test as cefepime-susceptible (S) or susceptible-dose dependent (SDD). However, there are no data to compare the cefepime testing performance of BD Phoenix automated susceptibility system (BD Phoenix) and disk diffusion (DD) relative to reference broth microdilution (BMD) against carbapenemase-producing (CP

Indexed as

Anti-Bacterial AgentsCarbapenem-Resistant EnterobacteriaceaeCefepimeMicrobial Sensitivity TestsCephalosporinsDisk Diffusion Antimicrobial TestsEnterobacteriaceae InfectionsHumansAnti-Bacterial AgentsCefepimeCephalosporinsbroth microdilutioncefepimedisk diffusionEnterobacteralesminor errorsPhoenix

Identifiers

PMID38712928
PMCPMC11237536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.